Litcius/Paper detail

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, L. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, A. Redondo, Reshma Rangwala, Signe Diness Vindeløv, M. Chen, Jeffrey R. Harris, Leonardo Nicacio, M. Teng, M.R. Smith, B.J. Monk, I. Vergote

2020Annals of Oncology25 citationsDOI

Topics & Concepts

MedicineBevacizumabInternal medicineAdverse effectNauseaPhases of clinical researchClinical endpointChemotherapyOncologySurgeryGastroenterologyClinical trialHER2/EGFR in Cancer ResearchCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research
LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study | Litcius